SCHEMBL14629932

SCHEMBL14629932

COc1cc(CI)cc(C(=O)Nc2ccc(CI)cc2)c1NC(=O)c1ccc(C(=N)N(C)C)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
F10 P00742 10/20 0.53
MAPT P10636 3/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
KCNH2 Q12809 1/20 0.41
NR1H4 Q96RI1 1/20 0.41
KLK1 P06870 1/20 0.41
KLK5 Q9Y337 1/20 0.41
NPC1 O15118 1/20 0.40
CASP3 P42574 1/20 0.40
RAB9A P51151 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
CYP2C9 P11712 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
ALDH1A1 P00352 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ROCK2 O75116 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14366485 0.93 F10 (0.52) F10MAPTMEN1KMT2AKLK1
SCHEMBL14629940 0.90 F10 (0.43) F10MAPTMEN1KMT2AKCNH2
SCHEMBL14632265 0.86 F10 (0.68) F10KCNH2
SCHEMBL14366484 0.83 F10 (0.59) F10MEN1KMT2AKCNH2NPC1
SCHEMBL14629881 0.83 LMNA (0.43) F10MAPTMEN1KMT2ANPC1
SCHEMBL14629865 0.82 LMNA (0.44) MAPTMEN1KMT2ANPC1RAB9A
SCHEMBL10179019 0.81 F10 (0.77) F10MEN1KMT2AKCNH2
SCHEMBL14345390 0.78 F10 (0.61) F10MAPTKCNH2KLK1KLK5
SCHEMBL14629943 0.77 F10 (0.56) F10KCNH2
SCHEMBL14632263 0.77 F10 (0.56) F10KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070021472-A1 N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility MILLENNIUM PHARMACEUTICALS, INC. 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021472-A1 N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility F2, TFPI, PLG F10 18/4885MAPT 4545/4885MEN1 2317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.